Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics for €8 million upfront plus up to $230 million in milestone payments and royalties. The sale marks the substantial completion of Lakefront's previously announced wind-down of legacy cell therapy activities, allowing the company to focus on its newly established T-cell engager pipeline while shareholders retain potential upside from future progress.